Ignite Creation Date:
2024-05-05 @ 8:02 PM
Last Modification Date:
2024-10-26 @ 9:57 AM
Study NCT ID:
NCT00789581
Status:
COMPLETED
Last Update Posted:
2017-07-02
First Post:
2008-11-11
Brief Title:
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
Phase III Study of DoxorubicinCyclophosphamide AC Followed by Ixabepilone vs AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status:
COMPLETED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TITAN
Brief Summary:
This is a randomized Phase III open-label multicenter study
Detailed Description:
Patients will be randomized in a 11 ratio to receive one of two different treatment arms Patients in treatment arm 1 will receive AC followed by ixabepilone Patients in treatment arm 2 will receive AC followed by weekly paclitaxel
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| TITAN | None | None | None |